BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,551,877 | -15.6% | 504,528 | 0.0% | 0.14% | -13.1% |
Q1 2023 | $4,207,764 | -45.5% | 504,528 | -25.0% | 0.16% | -45.2% |
Q4 2022 | $7,722,653 | +75.3% | 672,705 | +92.4% | 0.29% | +62.2% |
Q3 2022 | $4,405,000 | +50.1% | 349,570 | +26.0% | 0.18% | +56.5% |
Q2 2022 | $2,935,000 | -8.2% | 277,434 | +41.1% | 0.12% | +2.7% |
Q1 2022 | $3,197,000 | +44.9% | 196,625 | -56.2% | 0.11% | +31.8% |
Q4 2017 | $2,206,000 | +30.2% | 449,255 | +39.0% | 0.08% | +39.3% |
Q3 2017 | $1,694,000 | – | 323,255 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |